Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Status:
Completed

Trial end date:
2018-02-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antidepressive Agents
Citalopram
Dexetimide
Duloxetine Hydrochloride
Esketamine
Sertraline
Venlafaxine Hydrochloride